How Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78%Zacks Investment Research • 05/09/23
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® RegistryGlobeNewsWire • 05/06/23
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/05/23
Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care ConferenceGlobeNewsWire • 04/26/23
Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023GlobeNewsWire • 04/13/23
Strength Seen in Sight Sciences, Inc. (SGHT): Can Its 5.6% Jump Turn into More Strength?Zacks Investment Research • 04/11/23
Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent OfficeGlobeNewsWire • 03/30/23
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023GlobeNewsWire • 02/23/23
Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT ConferenceGlobeNewsWire • 02/22/23
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 01/09/23
Verana Health and Sight Sciences Collaborate on Glaucoma Research Using Curated Real-World Data from the IRIS RegistryPRNewsWire • 01/04/23
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 MonthsGlobeNewsWire • 12/08/22
Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare ConferenceGlobeNewsWire • 11/22/22
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022GlobeNewsWire • 10/20/22
Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)GlobeNewsWire • 09/29/22